GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » Beneish M-Score

Inhibrx (Inhibrx) Beneish M-Score : 2.80 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibrx Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 2.8 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Inhibrx's Beneish M-Score or its related term are showing as below:

INBX' s Beneish M-Score Range Over the Past 10 Years
Min: -14.71   Med: -0.77   Max: 4.7
Current: 2.8

During the past 7 years, the highest Beneish M-Score of Inhibrx was 4.70. The lowest was -14.71. And the median was -0.77.


Inhibrx Beneish M-Score Historical Data

The historical data trend for Inhibrx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Beneish M-Score Chart

Inhibrx Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - -3.09 0.48 -4.56 -1.04

Inhibrx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.51 4.70 3.46 -1.04 2.80

Competitive Comparison of Inhibrx's Beneish M-Score

For the Biotechnology subindustry, Inhibrx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Inhibrx's Beneish M-Score falls into.



Inhibrx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Inhibrx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 7.1742+0.528 * 1+0.404 * 1.2743+0.892 * 1.393+0.115 * 1.2947
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.053+4.679 * -0.187718-0.327 * 1.0208
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $3.04 Mil.
Revenue was 0 + 1.634 + 0.119 + 0.03 = $1.78 Mil.
Gross Profit was 0 + 1.634 + 0.119 + 0.03 = $1.78 Mil.
Total Current Assets was $274.54 Mil.
Total Assets was $288.58 Mil.
Property, Plant and Equipment(Net PPE) was $9.45 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.26 Mil.
Selling, General, & Admin. Expense(SGA) was $32.96 Mil.
Total Current Liabilities was $71.87 Mil.
Long-Term Debt & Capital Lease Obligation was $205.14 Mil.
Net Income was -78.71 + -93.604 + -51.789 + -47.052 = $-271.16 Mil.
Non Operating Income was -0.059 + -0.158 + -0.135 + -0.217 = $-0.57 Mil.
Cash Flow from Operations was -63.05 + -56.821 + -54.245 + -42.299 = $-216.42 Mil.
Total Receivables was $0.30 Mil.
Revenue was 0.017 + 0.274 + 0.278 + 0.711 = $1.28 Mil.
Gross Profit was 0.017 + 0.274 + 0.278 + 0.711 = $1.28 Mil.
Total Current Assets was $243.78 Mil.
Total Assets was $253.72 Mil.
Property, Plant and Equipment(Net PPE) was $6.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.21 Mil.
Selling, General, & Admin. Expense(SGA) was $22.47 Mil.
Total Current Liabilities was $32.64 Mil.
Long-Term Debt & Capital Lease Obligation was $205.94 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.038 / 1.783) / (0.304 / 1.28)
=1.70387 / 0.2375
=7.1742

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.28 / 1.28) / (1.783 / 1.783)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (274.538 + 9.453) / 288.577) / (1 - (243.777 + 6.775) / 253.716)
=0.015892 / 0.012471
=1.2743

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.783 / 1.28
=1.393

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.213 / (1.213 + 6.775)) / (1.256 / (1.256 + 9.453))
=0.151853 / 0.117285
=1.2947

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(32.958 / 1.783) / (22.469 / 1.28)
=18.484577 / 17.553906
=1.053

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((205.139 + 71.87) / 288.577) / ((205.943 + 32.64) / 253.716)
=0.959914 / 0.940355
=1.0208

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-271.155 - -0.569 - -216.415) / 288.577
=-0.187718

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Inhibrx has a M-score of 2.80 signals that the company is likely to be a manipulator.


Inhibrx Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Inhibrx's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx (Inhibrx) Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Executives
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe director, 10 percent owner, officer: Chief Executive Officer 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman director, 10 percent owner, officer: Chief Scientific Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem director, 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner officer: Chief Medical Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121

Inhibrx (Inhibrx) Headlines